Jason X. Cheng to Neoadjuvant Therapy
This is a "connection" page, showing publications Jason X. Cheng has written about Neoadjuvant Therapy.
Connection Strength
0.624
-
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity. World J Surg Oncol. 2014 Nov 06; 12:329.
Score: 0.396
-
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. Eur J Surg Oncol. 2019 Aug; 45(8):1498-1504.
Score: 0.134
-
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. J Surg Oncol. 2008 Jul 01; 98(1):34-41.
Score: 0.064
-
Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease? Dig Surg. 2018; 35(2):104-110.
Score: 0.030